BWAY Brainsway

Sandhya Prashad, M.D., Now Offering BrainsWay Deep TMS to Patients With Depression in Houston Area

Sandhya Prashad, M.D., Now Offering BrainsWay Deep TMS to Patients With Depression in Houston Area

BELLAIRE, Texas, July 10, 2018 (GLOBE NEWSWIRE) -- Houston psychiatrist Sandhya Prashad, M.D., today announced that her practice is now offering BrainsWay Deep Transcranial Magnetic Stimulation (Deep TMS) to patients with depression. The facility will be the first in the region to offer the treatment.

“We’ve always prided ourselves in offering the most advanced medicine to our patients,” Dr. Prashad said. “Deep TMS ensures that we are providing just that. With almost half of those suffering from depression unable to respond to antidepressant medications, being able to provide relief to patients that are otherwise treatment resistant is a great opportunity.”

BrainsWay Deep TMS is a safe, FDA-approved, non-invasive treatment for depression. The cushioned helmet stimulates the prefrontal cortex of the brain – the region involved in depression. Brief 20-minute treatments allow for little to no disruption in a patient’s daily activity. Immediately after treatment, patients are able to drive home and return to their routine, including work commitments. Deep TMS has been tested and proven in over 60 clinical studies in leading institutions worldwide.

Dr. Prashad first took an interest in treatment resistant disorders during her time at Baylor College of Medicine and opened her first mental health practice in the Houston area seven years ago. The new TMS facility is located at 6565 West Loop South, #500B in Bellaire, Texas. Patients may learn more about the treatment and the practice by calling 832-730-5196 or visiting

About Dr. Sandhya Prashad

Dr. Sandhya Prashad is a board-certified psychiatrist who obtained a Bachelor of Science in Biochemistry from the University of Texas at Austin and then obtained her Doctor of Medicine at Baylor College of Medicine in 2007. Dr. Prashad is the founder and medical director of Houston TMS Therapeutics and . She has a special interest in treating depression and bipolar disorder, especially those cases which are treatment resistant. 

Dr. Prashad was named one of Houston’s Top Doctors by H Texas Magazine for 2017. She is also a founding member and the secretary of the American Society of Ketamine Physicians, which is a non-profit organization created to advocate for the safe use of ketamine for mental illness and pain disorders and to expand access to ketamine therapy.

About BrainsWay

BrainsWay Ltd./ BrainsWay USA (TASE:BRIN), is a leader in noninvasive treatments for brain disorders utilizing Deep Transcranial Magnetic Stimulation (Deep TMS). Our unique patented technology was developed in collaboration with the National Institute of Health (NIH) and is FDA and CE cleared to treat patients with depression who are not currently responding to medication. The treatment has been enthusiastically supported by many academic communities and is widely covered by most insurance payers. For more information, please visit .

Media Contact:

Nechama Feuerstein



201-373-2228

EN
10/07/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Brainsway

 PRESS RELEASE

BrainsWay to Report Fourth Quarter and Full Year 2025 Financial Result...

BrainsWay to Report Fourth Quarter and Full Year 2025 Financial Results on March 11, 2026 BURLINGTON, Mass. and JERUSALEM, Feb. 25, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation technologies, today announced that it will report its fourth quarter and full year 2025 financial results, as well as operational highlights, before the open of the U.S. financial markets on Wednesday, March 11, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the res...

 PRESS RELEASE

BrainsWay to Participate in the Citi 2026 Unplugged MedTech and Life S...

BrainsWay to Participate in the Citi 2026 Unplugged MedTech and Life Sciences Access Day BURLINGTON, Mass. and JERUSALEM, Feb. 23, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced that management will participate in one-on-one meetings at the Citi 2026 Unplugged MedTech and Life Sciences Access Day on Thursday, February 26, 2026, in New York, NY. Please contact your Citi representative to request a meeting at the conference. About BrainsWayBrainsWay is a g...

 PRESS RELEASE

BrainsWay Announces New Minority-Stake Investment in Canadian Provider...

BrainsWay Announces New Minority-Stake Investment in Canadian Provider, BrainStim Health Inc. BrainsWay continues to actively evaluate similar investments in leading North American mental health providers to raise awareness and expand access to transformative care BURLINGTON, Mass. and JERUSALEM, Feb. 19, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced it has entered into a strategic equity financing agreement with BrainStim Health...

 PRESS RELEASE

BrainsWay Reports Cigna’s Evernorth Behavioral Health to Eliminate Pri...

BrainsWay Reports Cigna’s Evernorth Behavioral Health to Eliminate Prior Authorization Requirements for TMS Coverage, Accelerating Access to Care BURLINGTON, Mass. and JERUSALEM, Feb. 18, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today commented on the recent  issued by Evernorth® Behavioral Health, Inc., a division of the Cigna Group, which serves over 18 million covered lives across 12 states, that it will no longer require prior authorization for transcranial magn...

 PRESS RELEASE

BrainsWay Announces Change in ADS-to-Ordinary Share Ratio

BrainsWay Announces Change in ADS-to-Ordinary Share Ratio Change in ADS ratio aimed at simplifying comparisons to ordinary shares traded on the Tel Aviv Stock Exchange, while boosting liquidity and access for U.S. investors BURLINGTON, Mass. and JERUSALEM, Feb. 17, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced that its Board of Directors approved a plan to change to the ratio of its American Depositary Shares (ADSs) listed on the Nasdaq Capital Market (...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch